Charles River Laboratories International Quarterly Income Statement
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Charles River Laboratories International revenue and earnings
In the quarter ended Jun 27, 2026, Charles River Laboratories International generated $1.00 billion in revenue, down 2.7% from the same quarter a year earlier. Charles River Laboratories International reported a net loss of $1.5 million, compared with net income of $52.3 million a year earlier. Operating margin was 11.9%.
Diluted earnings per share came in at -$0.03, down from $1.06.
Summary generated from market data by MetaCap's automated system. Methodology
Charles River Laboratories International income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-27 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-28 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-30 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.00B | 995.83M | 994.23M | 1.00B | 1.03B | 984.17M | 1.00B | 1.01B | 1.03B | 1.01B | 1.01B | 1.03B |
| Revenue growth (YoY) | -2.72% | +1.18% | -0.83% | -0.49% | +0.59% | -2.71% | -1.08% | -1.64% | -3.19% | -1.73% | -7.85% | +3.79% |
| Cost of Revenue | — | — | — | — | — | — | — | 660.74M | 672.40M | 666.72M | — | 664.78M |
| Gross Profit | — | — | — | — | — | — | — | 349.02M | 353.71M | 344.84M | — | 361.84M |
| Operating Expenses | — | — | — | — | — | — | — | 231.62M | 202.06M | 218.87M | — | 210.34M |
| Selling, General & Admin | 228.90M | 159.42M | 196.14M | 177.59M | 191.55M | 177.80M | 195.71M | 199.21M | 169.79M | 186.29M | 197.14M | 176.11M |
| Operating Income | 119.89M | 119.90M | -283.44M | 133.80M | 100.13M | 74.67M | -167.69M | 117.41M | 151.65M | 125.98M | 132.92M | 151.50M |
| Interest Expense | 30.34M | 26.74M | 23.77M | 25.40M | 29.97M | 27.88M | 28.23M | 30.28M | 32.77M | 35.00M | 33.54M | 33.74M |
| Other Income (Expense) | -37.41M | -124.13M | 12.10M | -22.62M | 154.00K | -12.21M | -22.70M | 2.59M | -2.24M | 5.83M | 107.74M | -6.26M |
| Income Tax | 53.93M | -15.14M | -17.81M | 31.64M | 18.73M | 10.10M | -3.04M | 20.95M | 25.39M | 24.53M | 19.75M | 24.85M |
| Net Income | -1.48M | -14.84M | -276.56M | 54.42M | 52.33M | 25.47M | -214.50M | 69.66M | 94.08M | 72.96M | 187.08M | 87.39M |
| Net Income growth (YoY) | -102.83% | -158.28% | — | -21.87% | -44.38% | -65.09% | -214.65% | -20.29% | -3.03% | -29.26% | -0.17% | -9.42% |
| EPS (Basic) | -0.03 | -0.30 | -5.58 | 1.11 | 1.06 | 0.50 | -4.20 | 1.34 | 1.75 | 1.31 | 3.66 | 1.70 |
| EPS (Diluted) | -0.03 | -0.30 | -5.57 | 1.10 | 1.06 | 0.50 | -4.17 | 1.33 | 1.74 | 1.30 | 3.63 | 1.69 |
| Shares Outstanding (Basic) | 48.02M | 48.95M | — | 49.21M | 49.15M | 50.68M | — | 51.39M | 51.55M | 51.44M | — | 51.28M |
| Shares Outstanding (Diluted) | 48.02M | 48.95M | — | 49.43M | 49.32M | 50.85M | — | 51.58M | 51.85M | 51.84M | — | 51.61M |
| EBITDA | 187.18M | 187.05M | -205.16M | 218.96M | 219.64M | 195.03M | -65.58M | 205.60M | 237.73M | 211.33M | 213.44M | 230.37M |
| Gross Margin | — | — | — | — | — | — | — | 34.56% | 34.47% | 34.09% | — | 35.25% |
| Operating Margin | 11.94% | 12.04% | -28.51% | 13.32% | 9.70% | 7.59% | -16.73% | 11.63% | 14.78% | 12.45% | 13.12% | 14.76% |
| Net Margin | -15.00% | -149.00% | -27.82% | 5.42% | 5.07% | 2.59% | -21.39% | 6.90% | 9.17% | 7.21% | 18.46% | 8.51% |
This table shows 12 quarterly periods of Charles River Laboratories International's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CRL's reporting calendar. What is a income statement?